-

Vesigen to Present at the 2023 Cell and Gene Meeting on the Mesa

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, today announced that Paulash Mohsen, Chief Executive Officer, will present at the 2023 Cell and Gene Meeting on the Mesa on October 12 at 9:15 AM PT in Carlsbad, CA.

A livestream of the presentation will be available to registered attendees within the conference virtual platform.

About Vesigen Therapeutics

Vesigen Therapeutics is a biotechnology company developing a novel, non-viral delivery technology for gene editing, RNA, and protein-based therapeutics. Vesigen’s patented technology, called ARMMs (ARRDC1 Mediated Microvesicles), can be used to precisely deliver a wide range of payloads to a unique set of tissue and cell types. Vesigen has demonstrated highly efficient in vitro and in vivo functional delivery of a range of payloads across multiple cell types and is committed to developing transformative medicines that address current unmet medical needs. ARMMs were discovered and engineered into a drug delivery system at the Harvard T.H. Chan School of Public Health.

For additional information visit www.vesigen.com.

Contacts

Investors and Media:
Adam Bero, Ph.D.
Kendall Investor Relations
abero@kendallir.com

Vesigen Therapeutics, Inc.


Release Versions

Contacts

Investors and Media:
Adam Bero, Ph.D.
Kendall Investor Relations
abero@kendallir.com

More News From Vesigen Therapeutics, Inc.

Vesigen Highlights Key in vivo and Targeted Tropism Data Advancements for Non-Viral Delivery Platform at 2024 ASGCT and ARVO Annual Meetings

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, recently showcased two data presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting and ten data presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. ARVO was held from May 5-9 in Seattle, Washington, while ASGCT was held from May 7-1...

Vesigen to Present New Preclinical Data on Ophthalmology Applications of Engineered ARMMs at 2024 ARVO Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, today announced that the Company will be presenting two posters sharing new preclinical data from its engineered ARMMs platform at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. The meeting will be held in Seattle, Washington from May 5-9. Vesigen’s technology compris...

Vesigen to Present New Preclinical Data on Engineered ARMMs Technology at 2024 ASGCT Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, today announced that the Company will be presenting 10 posters sharing new preclinical data from its engineered ARMMs platform at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. The conference will be held from May 7-11 in Baltimore, Maryland. Vesigen’s delivery technology has...
Back to Newsroom